Agreement expands Mycovia’s commercialization that is global for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia continues to rapidly develop VT-1161 as a prospective first FDA-approved remedy for recurrent vulvovaginal candidiasis
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a unique permit and development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia as well as other CIS nations. VT-1161, a dental antifungal item prospect, happens to be in period 3 medical studies when it comes to remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts nearly 138 million females global every year.
“We are excited to partner with Gedeon Richter, a business with strong market leadership in women’s health, to build up and commercialize VT-1161, our prospective first FDA-approved treatment plan for RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 russian brides meeting their foreign husbands in worldwide areas. “Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand” bővebben